This filing is a standard corporate update with no immediate trading catalyst. Monitor for actual partnership announcements or financial results that could validate the pipeline progress. The recent ATM offering and going concern risk remain the dominant factors for EVGN's near-term outlook.
Price Chart
Executive Summary
Evogene Ltd. filed a 6-K containing an investor presentation that highlights its ChemPass AI platform, pipeline progress in pharma and ag-chem, and a second collaboration with Google Cloud initiated in February 2026. The presentation is forward-looking and contains no new financial data, material agreements, or operational milestones. Given the company's recent $2.9M ATM offering, Nasdaq non-compliance, and going concern risk flagged in its annual report, this filing is a routine corporate update with limited stock-moving potential.
Key Facts
- Evogene filed an investor presentation as Exhibit 99.1 to its 6-K.
- The presentation describes the ChemPass AI platform for multi-parameter small-molecule generation.
- A second collaboration with Google Cloud was initiated in February 2026 to integrate AI agents.
- The pharma pipeline includes collaborations for oncology, metabolism, immunology, and neurology, plus internal programs.
- The ag-chem subsidiary AgPlenus has herbicide (APCO-12) and fungicide (APTF-1/APTF-4) programs, including a wheat blotch internal pipeline.
- The business strategy focuses on co-development partnerships with pharma, ag-chem, and biotech companies.
- No financial figures, guidance, or material definitive agreements were disclosed in the filing.
Financial Impact
No financial impact from this filing; it is a forward-looking presentation without new financial data.
Risk Factors
- Going concern risk as noted in the 20-F annual report.
- Nasdaq minimum bid price non-compliance and potential delisting.
- Dilution from the recent ATM offering of up to $2.9M.
- Pre-revenue status with limited cash runway ($8.5M as of March 31, 2026).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003200 |
| Document: zk2635546.htm | 0001178913-26-003200 |
| Document: 0001178913-26-003200-index-headers.html | 0001178913-26-003200 |
| Document: 0001178913-26-003200-index.html | 0001178913-26-003200 |
| Document: 0001178913-26-003200.txt | 0001178913-26-003200 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $0.3641 | awaiting T+60 | — | $0.3638 (−0.08%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4106 | awaiting T+60 | — | $0.3638 (−11.40%) |
Oct 6, 2026 21d ago | 6-K | $0.4106 | awaiting T+60 | — | $0.3638 (−11.40%) |
Sep 30, 2026 27d ago | 6-K | $0.4000 | awaiting T+60 | — | $0.3638 (+9.05%) |
Sep 30, 2026 27d ago | EFFECT | $0.4000 | awaiting T+60 | — | $0.3638 (+9.05%) |
Sep 4, 2026 7w ago | 6-K | $0.5379 | awaiting T+60 | — | $0.3638 (−32.37%) |
Aug 18, 2026 10w ago | 6-K | $0.5826 | awaiting T+60 | — | $0.3638 (−37.56%) |
Aug 14, 2026 10w ago | Press Release | $0.6008 | awaiting T+60 | — | $0.3638 (−39.45%) |
Jul 31, 2026 12w ago | 6-K | $0.5400 $0.3466 | ▼ −35.81% | ▼ −37.60% | $0.3638 (−32.63%) |
Jun 16, 2026 19w ago | 6-K | $0.5600 $0.4806 | ▼ −14.18% | ▼ −15.18% | $0.3638 (−35.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers